Can chocolate go bad? Yes (!) What to know before sharing Valentine's Day treats
Can chocolate go bad? Yes (!) What to know before sharing Valentine's Day treats
Show Caption
Hide Caption
An expert explains the health benefits of eating chocolate
Sometimes having a sweet tooth can be good! Nutrition therapist Lauren Kelly explains some of the health benefits of eating chocolate.
A chocolate bar hates to see Valentine's Day coming.
The holiday is responsible for roughly $4 billion in chocolate and candy sales annually, according to a report from the U.S. Chamber of Commerce. Think Hershey's Kisses and pink-colored M&Ms to chocolate-covered strawberries and gourmet chocolate boxes.
Whether you're making a chocolatey treat, giving a loved one a box of chocolates or planning on enjoying some yourself, dietitian Jamie Nadeau, RD, shares some tips on how to make sure your Valentine's Day chocolate intake doesn't make you (love) sick.
Cute: I searched the country for a Valentine's date. Here's who I picked.
Can chocolate go bad?
The short answer is yes, chocolate can go bad.
The long answer is that it depends on a number of factors, including the type of chocolate and how it's stored, Nadeau explains. In general, dark chocolate usually lasts longer than milk chocolate because it doesn't contain milk.
"Most chocolate can last anywhere between one to two years, but it depends, so I recommend taking a peek at the expiration date and storing it properly," Nadeau says. "It should be stored in a cool, dry and dark place away from heat and sunlight."
Is candy a healthy Valentine's snack? Experts share how to have a healthy holiday.
How can you tell if chocolate has gone bad?
Many solid forms of chocolate can still be safely eaten up to six months past the best buy date on their label, Nadeau says, adding that "many expiration dates refer to optimal quality versus the food actually going bad right on that date." In other words, eating something like chocolate past its "best by" date usually just means it won't taste as good, not that it'll make you sick.
But if the chocolate in question has a "rancid smell," noticeable mold on top or a sour taste, that should be your sign to toss it out. Literal death by chocolate isn't necessarily something to worry about, but Nadeau notes that "just like other types of spoiled food, you can get food poisoning or gastrointestinal upset by eating chocolate that isn't good anymore."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Multiple Sclerosis Market to Grow Rapidly at a CAGR of 3.8% During the Forecast Period (2025-2034)
The multiple sclerosis market is growing due to rising prevalence, earlier diagnosis, and wider access to care. Demand is fueled by advancements in DMTs and emerging BTK inhibitors, which offer targeted, high-efficacy options, especially for progressive forms with limited existing therapies. LAS VEGAS, June 11, 2025 /PRNewswire/ -- Multiple sclerosis is a long-term autoimmune disorder in which the immune system mistakenly attacks the protective sheath surrounding nerves in the brain and spinal cord. This interference disrupts the flow of signals between the brain and the rest of the body, leading to symptoms such as fatigue, muscle weakness, vision disturbances, and difficulty with mobility. The severity and progression of multiple sclerosis can vary greatly among individuals. As of 2024, there were an estimated 1.6 million diagnosed cases of multiple sclerosis across the 7MM. This number is expected to increase at a CAGR of 1.4% over the forecast period from 2025 to 2034. The therapeutic landscape for multiple sclerosis has undergone a significant transformation, spurred by progress in both drug-based and supportive treatment approaches. Although MS remains without a cure, the market is seeing an expanding array of disease-modifying therapies (DMTs), greater personalization of care, and innovations in how treatments are delivered—all aimed at enhancing patient outcomes and quality of life. Pharmacologically, multiple sclerosis treatment involves both immediate and long-term strategies. For managing acute relapses, high-dose intravenous corticosteroids, most commonly methylprednisolone, continue to be the primary treatment, usually given over 3 to 5 days and followed by a course of tapering oral steroids. Learn more about the multiple sclerosis therapeutics market @ Multiple Sclerosis Drugs Market Intravenous corticosteroids, such as methylprednisolone, are effective for treating acute multiple sclerosis relapses but do not impact the long-term course of the disease. Ongoing disease management relies on disease-modifying therapies (DMTs), selected based on the severity of MS and individual patient requirements, to reduce relapse frequency and delay disability progression. While older injectable multiple sclerosis treatments like PLEGRIDY are still used, newer oral options like MAYZENT, VUMERITY, and MAVENCLAD provide greater convenience and may improve patient adherence. High-efficacy monoclonal antibodies (mAbs), including OCREVUS (now also available in a subcutaneous form), KESIMPTA, and BRIUMVI, are increasingly preferred for home-based therapy. Although LEMTRADA is a potent option, its use is restricted due to safety risks and its inclusion in the REMS program. As key multiple sclerosis drugs such as TYSABRI, TECFIDERA, AUBAGIO, and GILENYA face generic competition, pricing and access are being reshaped. In response, originator companies are shifting focus to next-generation treatments and improved formulations, such as subcutaneous versions and enhanced safety features, to retain market share. Supportive therapies also play a critical role; rehabilitation via exercise and physiotherapy can improve mobility and reduce fatigue, especially in progressive multiple sclerosis. Cognitive behavioral therapy (CBT) and mindfulness strategies help manage mood disorders like depression and anxiety, which in turn support treatment adherence. Additionally, lifestyle modifications involving diet, sleep hygiene, and vitamin D intake aid in symptom control. Assistive devices and occupational therapy further promote independence and enhance quality of life. Find out more on FDA-approved multiple sclerosis medication @ Multiple Sclerosis Treatments Multiple sclerosis treatment lacks neuroprotective and remyelinating therapies, with limited options for progressive multiple sclerosis. Current drugs focus on immune modulation but fail to reverse damage or halt progression. Diagnostic delays remain common due to nonspecific symptoms and limited biomarkers. There is a critical need for early detection tools, personalized therapies, and agents targeting neurodegeneration to improve outcomes in multiple sclerosis. The multiple sclerosis treatment pipeline remains robust, with promising candidates like Remibrutinib, Tolebrutinib, Fenebrutinib, and CNM-Au8 targeting novel mechanisms such as BTK inhibition and neuroprotection. Other multiple sclerosis drugs in the pipeline include Frexalimab (SAR441344) (Sanofi), Vidofludimus calcium (IMU-838) (Immunic Therapeutics), Masitinib (AB Science), PIPE-307 (Contineum Therapeutics), and others. These multiple sclerosis pipeline therapies reflect an increasing emphasis on progressive multiple sclerosis and remyelination to improve long-term outcomes. Discover which therapies are expected to grab major multiple sclerosis market share @ Multiple Sclerosis Treatment Market Tolebrutinib is an oral BTK inhibitor designed to penetrate the blood–brain barrier, targeting both B cells and microglia to mitigate smoldering neuroinflammation in multiple sclerosis (MS). By focusing on central nervous system (CNS) processes that drive neurodegeneration, it aims to address disease progression beyond peripheral inflammation. In March 2025, the US FDA accepted tolebrutinib for priority review as a treatment for non-relapsing secondary progressive multiple sclerosis, to slow relapse-independent disability progression. A decision is anticipated by September 2025, with a parallel evaluation ongoing in the EU. Vidofludimus calcium is an investigational oral therapy currently in Phase III trials for relapsing multiple sclerosis and Phase II for progressive multiple sclerosis. It combines DHODH inhibition for immune regulation with Nurr1 activation for potential neuroprotective effects, aiming to target key mechanisms of neurodegeneration. In April 2025, Immunic reported positive outcomes from the Phase II CALLIPER trial, supporting vidofludimus calcium's role as a Nurr1 activator in progressive multiple sclerosis patients. Fenebrutinib is an innovative, oral, reversible, non-covalent BTK inhibitor in Phase III development for MS. By modulating both adaptive and innate immune responses via B cells and microglia, it offers a dual approach to controlling disease activity and slowing disability. It is currently the only reversible BTK inhibitor in late-stage multiple sclerosis trials. The Phase III program includes FENhance 1 and 2 studies in relapsing multiple sclerosis (vs. teriflunomide) and the FENtrepid trial in primary progressive multiple sclerosis (vs. ocrelizumab), marking the first head-to-head comparison of a BTK inhibitor with an approved PPMS therapy. Regulatory submissions for both RMS and PPMS are planned for 2026. In September 2024, Roche presented 48-week results from the FENopta Phase II open-label extension at the 40th ECTRIMS Congress. Remibrutinib is an oral covalent BTK inhibitor under investigation for multiple sclerosis and chronic spontaneous urticaria (CSU), where it blocks BTK signaling to prevent histamine release. While no Phase I or II trials have yet been conducted for multiple sclerosis, remibrutinib is in Phase III development for CSU through the REMODEL-1 and REMODEL-2 trials. Primary completion is expected in 2026, with regulatory submission anticipated in 2027. Earlier Phase IIb CSU data showed favorable safety and tolerability. CNM-Au8 is an oral gold nanocrystal therapy designed to address mitochondrial dysfunction in multiple sclerosis by boosting NAD+ production, enhancing antioxidant capacity, and activating the heat shock factor-1 pathway to support protein homeostasis. Although the VISIONARY-MS Phase II trial was halted early due to COVID-19, CNM-Au8 is being evaluated in the ongoing Phase II REPAIR-MS trial. Results from REPAIR-MS, along with a planned FDA End-of-Phase II meeting in 2025, will inform the design of a global Phase III trial. In April 2025, Clene Nanomedicine presented promising new data at the AAN Annual Meeting, showing meaningful improvements in cognition and visual function from the VISIONARY-MS open-label extension. Masitinib is being developed for progressive multiple sclerosis with a focus on inhibiting mast cells and microglia, key players in chronic neuroinflammation. This approach aims to slow progression in patients with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive multiple sclerosis (SPMS). Following positive results from a Phase IIb/III study, a confirmatory Phase III trial is ongoing. In September 2024, AB Science provided an update on masitinib's development at the ECTRIMS 2024 conference. Discover more about the multiple sclerosis pipeline @ Multiple Sclerosis Clinical Trials The anticipated launch of these emerging therapies for multiple sclerosis are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the multiple sclerosis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the market size for Multiple Sclerosis is expected to grow from USD 20 billion in the 7MM in 2024 at a 3.8% CAGR by 2034. This expansion across the 7MM will be driven by the introduction of innovative therapies, remibrutinib, tolebrutinib, fenebrutinib, frexalimab, vidofludimus calcium, CNM-Au8, and masitinib, among others. Furthermore, multiple sclerosis prevalence is rising due to modifiable environmental and lifestyle factors like Epstein-Barr virus, low vitamin D, smoking, obesity, and night shifts, with genetics and geography also contributing. DelveInsight's latest published market report, titled Multiple Sclerosis – Market Insight, Epidemiology, and Market Forecast – 2034, will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the multiple sclerosis country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The multiple sclerosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Diagnosed Prevalent Cases of Multiple Sclerosis Gender-specific Diagnosed Prevalent Cases of Multiple Sclerosis Phenotype-specific Diagnosed Prevalent Cases of Multiple Sclerosis EDSS-specific Diagnosed Prevalent Cases of Multiple Sclerosis The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM multiple sclerosis market. Highlights include: 10-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this multiple sclerosis market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the multiple sclerosis market. Also, stay abreast of the mitigating factors to improve your market position in the multiple sclerosis therapeutic space. Related Reports Multiple Sclerosis Epidemiology Forecast Multiple Sclerosis Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted multiple sclerosis epidemiology in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan. Multiple Sclerosis Pipeline Multiple Sclerosis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key multiple sclerosis companies, including Sanofi, Immunic, InnoCare Pharma, Tiziana Life Sciences, Biogen, Bristol-Myers Squibb, ImStem Biotechnology, Idorsia Pharmaceuticals, among others. Relapsing-Remitting Multiple Sclerosis Market Relapsing-Remitting Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key RRMS companies including Mapi Pharma, Apimeds, Genentech (Roche), Merck, Clene Nanomedicine, InnoCare Pharma, Oryzon Genomics, among others Relapsing-Remitting Multiple Sclerosis Pipeline Relapsing-Remitting Multiple Sclerosis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key RRMS companies, including TG Therapeutics, Novartis, Sanofi, CinnaGen, Immunic, Mapi Pharma, Apimeds, Genentech (Roche), Merck, Clene Nanomedicine, InnoCare Pharma, Oryzon Genomics, GeNeuro SA, GlaxoSmithKline, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP
Yahoo
7 hours ago
- Yahoo
America might finally make childbirth free—and moms could be the biggest winners
'This is how much it costs to give birth in America: $44,318.41.' That was the now-viral TikTok from a mom just days postpartum, scrolling through the itemized bill at home. Her insurance only covered $20,353.62—despite paying $2,500 a month for coverage for her family of five. This mom's story isn't an outlier. According to the Peterson-KFF Health System Tracker, privately insured families in the U.S. pay an average of $3,000 out-of-pocket for childbirth on average—just for having a baby. By 'choosing' to have a baby with a midwife in a birth center, I personally had to pay a $10k fee upfront. (Wanting midwifery care in a calm setting for my super fast labors didn't feel like a choice, but in America, it is.) Moms bear so many burdens for having babies. And one devastating cost that sets so many families back financially when they're just beginning life together is the price of childbirth, even with insurance. We're talking million-dollar NICU bills. $50k c-section charges. A financial punishment for doing the most critical work in a country: bringing the next generation of citizens into the world. But that may soon change. A bipartisan group of senators has introduced a bill that could be a game-changer for millions of American families. The Supporting Healthy Moms and Babies Act (S.1834) was announced on May 21, 2025, and aims to eliminate all out-of-pocket costs related to prenatal care, childbirth, and postpartum services for those with private health insurance. The bill's sponsors—Sens. Cindy Hyde-Smith (R-MS), Tim Kaine (D-VA), Josh Hawley (R-MO), and Kirsten Gillibrand (D-NY)—say the legislation is about protecting families from being buried in medical debt at one of the most vulnerable times in life. 'Bringing a child into the world is costly enough without piling on cost-share fees that saddle many mothers and families with debt,' Sen. Hyde-Smith said in a statement announcing the legislation. 'By relieving financial stresses associated with pregnancy and childbirth, hopefully more families will be encouraged to embrace the beautiful gift and responsibility of parenthood.' A companion bill is expected in the House, led by Rep. Jared Golden (D-ME), who told Vox, 'This idea is simple and powerful: Pregnancy and childbirth are normal parts of family life. So, insurance companies should treat it like the routine care it is and cover the cost—not stick people with huge medical bills.' While the average out-of-pocket cost is around $3,000, the financial burden can be far worse for many: 17% of privately insured moms face bills over $5,000 1% are hit with bills exceeding $10,000 17.5% of women with private insurance report problems paying medical bills Nearly 9% say they couldn't pay them at all These numbers are not just statistics—they represent real parents delaying care, going into debt, or struggling to recover financially in the fragile weeks after childbirth. If passed, the bill would expand the list of 'essential health benefits' under the Affordable Care Act to include full-spectrum maternity care. Medicaid already covers these services in full, and that's how 41% of births in the U.S. are paid for. But for the 178 million people on private insurance plans? Birth is still a budget-buster. The new legislation would require private insurers to pick up the tab. That means: Prenatal care (including appointments and ultrasounds) Labor and delivery Hospital stays Postpartum recovery and mental health care Neonatal and perinatal services Lactation support The estimated premium hike to cover it all? About $30 per year, according to Lawson Mansell, policy analyst at the Niskanen Center, who conducted the cost modeling for the bill. Mansell told Vox this proposal is the simplest way, on an administrative level, to make birth free. Related: Too many U.S. moms are in debt from giving birth. They deserve better. Beyond the financial relief, this bill has the potential to improve health outcomes for moms and babies. Research backs this up: A report by the Washington State Office of the Insurance Commissioner found that eliminating cost-sharing for prenatal services is associated with improved maternal and infant outcomes, including fewer preterm births and higher birth weights. So in addition to relieving the stress families face, covering prenatal care fully makes it more likely that moms actually get it. Another study published in BMC Public Health linked removing financial barriers under the Affordable Care Act to increased use of preventive care, such as mammography and Pap tests. While the study focused on these services, the findings suggest that eliminating financial barriers can encourage timely and consistent healthcare utilization. The bill's sponsors come from across the political spectrum—and so do its supporters. Everyone from the American Medical Association and the American College of Obstetricians and Gynecologists to anti-abortion groups like Americans United for Life and Susan B. Anthony Pro-Life America have voiced support. Even Planned Parenthood Action Fund commented they 'generally supports legislation to make the cost of maternal health care and parenting more affordable.' Related: The cost of giving birth is getting more expensive—and some families are getting hit with childbirth debt If the bill becomes law, the financial landscape of pregnancy would change dramatically—especially for those in the 'missing middle': families who earn too much for Medicaid but not enough to easily afford thousands in delivery fees. It would also offer immediate relief for parents managing multiple financial burdens at once: high rent, unpaid leave, child care costs, student loans. You know, new motherhood. Call your representatives. Especially if you have private insurance and have ever been slammed with a delivery bill. You can find contact info at and Share your story. Lawmakers have said constituent birth bill stories played a big role in shaping this legislation. Talk about it on social. If your childbirth costs shocked you, say so. Use hashtags like #MakeBirthFree and tag your reps. This moment is historic not just because it's bipartisan, but because it signals a new kind of family policy thinking: one where moms aren't expected to 'figure it out' in isolation, one giant bill at a time. As Yuval Levin of the American Enterprise Institute put it in a policy brief, 'Substantively and symbolically, bringing the out-of-pocket health care costs of childbirth to zero is an ambitious but achievable starting point for the next generation of pro-family policies.' Whether you're pregnant now or years past it, you probably remember your hospital bill—and you definitely remember how it made you feel. Exhausted. Angry. Maybe even ashamed. This new bill says: No more. And moms deserve that. Sources: Family-Friendly Policies for the 119th Congress. February 2025. AEI. Family-Friendly Policies for the 119th Congress. America might finally make childbirth free. May 2025. Vox. America might finally make childbirth free. Americans United for Life Applauds Bipartisan Innovative Policy Proposal. May 2025. America United for Life. Americans United for Life Applauds Bipartisan Innovative Policy Proposal to Make Maternal Healthcare More Affordable. AMA advocacy to improve maternal health. May 2025. AMA. AMA advocacy to improve maternal health. Impact of removing cost sharing. 2019. BMC Public Health. Impact of removing cost sharing under the affordable care act (ACA) on mammography and pap test use. New bipartisan proposal would remove childbirth costs. May 2025. Niskanen Center. New bipartisan proposal would remove childbirth costs and confusion for parents. Characteristics of Mothers by Source of Payment for the Delivery. May 2023. CDC. Characteristics of Mothers by Source of Payment for the Delivery: United States, 2021. About the Affordable Care Act. Us Department of Health an Human Services. About the Affordable Care Act. Out-of-pocket medical bills childbirth. National Library of Medicine. Out-of-pocket medical bills from first childbirth and subsequent childbearing. The Association of Childbirth with Medical Debt. National Library of Medicine. The Association of Childbirth with Medical Debt in the USA, 2019–2020. Sentators introduce bill to ease financial burden of pregnancy. Cindy Hyde-Smith. SENATORS INTRODUCE BIPARTISAN BILL TO EASE THE FINANCIAL BURDEN OF PREGNANCY, CHILDBIRTH. Women who Give Birth Incur Nearly $19,000 in Additional Health Costs. KFF. Women who Give Birth Incur Nearly $19,000 in Additional Health Costs, Including $2,854 More that They Pay Out of Pocket.
Yahoo
9 hours ago
- Yahoo
MERGE Continues Growth Trajectory with Strategic Additions to Leadership
CHICAGO, June 11, 2025--(BUSINESS WIRE)--MERGE, a leading marketing and technology agency, announces two strategic hires to strengthen and further accelerate its mission of integrated growth and innovation. Heidi West steps into the role of Chief Revenue Officer, and John Bracey joins MERGE as Chief Data and Performance Officer. These accomplished executives bring decades of experience and expertise, fortifying the agency's leadership team as it continues to expand at the intersection of health and wellness. Heidi West, MERGE's new Chief Revenue Officer, offers over 30 years of exceptional sales leadership and a history of delivering impactful technology solutions across healthcare, including at CommonSpirit Health, Englewood Health, Mount Sinai Health System, Stanford Health Care, and other diverse industries. Most recently leading the healthcare team at Zoom, West has held sales and leadership roles at Cisco, Nutanix, and Booz Allen. "I am incredibly excited to join MERGE at such a pivotal time," said West. "I look forward to leveraging my experience in healthcare and technology to help MERGE bridge the gap between health and consumer verticals. By focusing on improving patient engagement and experience, we can deliver trusted, relatable solutions guided by AI and data-driven strategies for our clients and their audiences." West's background in healthcare and executive engagement, combined with her talent for building high-performing sales teams aligned with strategic goals, makes her an invaluable catalyst for strategic growth. Commenting on this significant leadership addition, Stephanie Trunzo, MERGE CEO, remarked, "While leading Oracle Health, I met Heidi in her role driving the health business at Zoom. Her extensive experience in the health industry, coupled with her strategic sales expertise and sincere approach will catalyze the outcome-oriented momentum of our client service and business development teams." Beyond her professional achievements, West is a passionate advocate for women in technology and STE(A)M initiatives. John Bracey, a visionary in data science and analytics, brings an impressive track record of transforming global brands into organizations driven by insight. Formerly EVP at Publicis Groupe, Bracey spearheaded data-driven transformation initiatives across a number of Publicis Groupe's largest consumer and healthcare brands. "My expertise lies where data science and strategy meet. I'm passionate about helping brands maximize the value of their data and media investments, whether by engineering insight or architecting performance," said Bracey. "Across industries, I've seen that an audience-first approach consistently drives better insights and stronger outcomes. At MERGE, I look forward to continuing this work, turning complex data into automated, actionable solutions that deliver measurable business outcomes." "John's ability to harness data to transform businesses will substantively enhance how we deliver personalized, meaningful solutions that unite people and brands. These data-smart offerings will be the electricity that runs through creative and tech implementations to identify, optimize, and predictively model impact. We're incredibly excited about the amplified innovation he will bring to MERGE," said Trunzo. The West and Bracey appointments further accelerate MERGE's strategic leadership expansion, building on the other significant executive announcements this year beginning with Stephanie Trunzo's announcement as CEO, and including Erica Denner (Chief People Officer), Kyle Smith (CTO), Paul Buranosky (CMO), and Chris Esposito (CFO). About MERGE MERGE is a marketing and technology agency built for the intersection of health and wellness. We combine deep expertise in health and consumer behavior with strategy, creativity, experience technology, and digital marketing to design personalized experiences that drive meaningful results. Powered by human insight, creativity, and AI, we weave storytelling through technology to turn complexity into clarity — strengthening relationships between people and brands. With 750+ specialists across Atlanta, Boston, Chicago, Denver, Kansas City, Los Angeles, New York, and Raleigh, MERGE partners with leading brands like Abbott, GE Healthcare, American Express, T-Mobile, Coach, and Meta to advance health, wellness, and happiness. Learn more at View source version on Contacts Mary Josephmjoseph@
